Person: AYDOĞAN, KENAN
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
AYDOĞAN
First Name
KENAN
Name
10 results
Search Results
Now showing 1 - 10 of 10
Publication A report of 13 cases of merkel cell carcinoma: Single-center experience and review of the literature(Korean Dermatological Assoc, 2019-06-01) Yazıcı, Serkan; Yazıcı, Elif Irmak; Adım, Şaduman Balaban; Başkan, Emel Bülbül; Aydoğan, Kenan; Sarıcaoğlu, Hayriye; YAZİCİ, SERKAN; Yazıcı, Elif Irmak; BALABAN ADIM, ŞADUMAN; BÜLBÜL BAŞKAN, EMEL; AYDOĞAN, KENAN; SARICAOĞLU, HAYRİYE; Tıp Fakültesi; Dermatoloji ve Zührevi Hastalıklar Ana Bilim Dalı; 0000-0001-6407-0962; 0000-0002-0193-1128; AAH-1388-2021; AAH-2459-2021; AAH-6216-2021; IHQ-3086-2023; EMN-0789-2022; DPU-8534-2022Background: There is limited data knowledge of Merkel cell carcinoma (MCC) in Turkey aside from a few case reports. Objective: The aim of this study was to describe the clinical characteristics, demographic features, therapeutic parameters, and outcome of primary cutaneous MCC cases from Turkey. Methods: Digital medical records of the 13 MCC patients who were followed-up at a tertiary referral center were retrospectively analyzed. Clinic, demographic, tumor characteristics, and survival of the patients were retrieved. Results: Most of our patients were elderly. Female predominance was noticed. The most common primary site of the tumors was the lower extremities. The overall survival was 42 months, 68% at first year, 68% at third years, and 29% at fifth years. Conclusion: This is the first largest report from Turkish population with female predominance, and lower extremity tendency.Publication Predictors of drug survival of biologic therapies in psoriasis patients (vol 45, pg 813, 2020)(Taylor & Francis, 2020-08-31) Zorlu, Özge; Başkan, Emel Bülbül; BÜLBÜL BAŞKAN, EMEL; Yazıcı, Serkan; YAZİCİ, SERKAN; Sığırlı, Deniz; SIĞIRLI, DENİZ; Budak, Ferah; BUDAK, FERAH; Sarıcaoğlu, Hayriye; SARICAOĞLU, HAYRİYE; Aydoğan, Kenan; AYDOĞAN, KENAN; Cevhertas, Laçin; Tıp Fakültesi; İmmünoloji Ana Bilim; 0000-0001-5555-130X; 0000-0001-6407-0962; 0000-0001-7625-9148; 0000-0002-0193-1128; 0000-0003-2287-3569; AAH-1388-2021; AAH-6216-2021; AAA-7472-2021; F-4657-2014; IZP-9398-2023; AAH-2459-2021Publication Clinical and demographical characteristics of familial Behcet's disease (southeast Marmara region)(Karger, 2019-01-01) Kalın, Zübeyde Ceylan; Sarıcaoğlu, Hayriye; Yazıcı, Serkan; Aydoğan, Kenan; Başkan, Emel Bülbül; SARICAOĞLU, HAYRİYE; YAZİCİ, SERKAN; AYDOĞAN, KENAN; BÜLBÜL BAŞKAN, EMEL; Tıp Fakültesi; Dermatoloji ve Zührevi Hastalıklar Ana Bilim Dalı; 0000-0001-6407-0962; 0000-0002-0193-1128; AAH-2459-2021; AAH-6216-2021; AAH-1388-2021; DQE-8993-2022Background: Familial aggregation in Behcet's disease (BD) has been reported in Turkish and Japanese populations. While the frequency of familial cases has been reported to be 2-5% worldwide, this rate reaches up to 15% in the Middle East. Objective: This study aimed to determine the incidence of familial BD cases followed in the BD polyclinic and to compare their clinical and demographic characteristics to those observed in sporadic cases. Methods: Data related to BD patients who were followed between 1995 and 2014 were collected from computerized archive records and were assessed for detailed family histories. Only first-degree relatives (brother, sister, mother, father, children) were considered to be cases of familial BD. Clinical and demographic features were retrieved. Our BD polyclinic is located in the Southeast Marmara Region in Turkey. Results: BD was detected in 36 first-degree relatives of 33 patients out of 840 patients with BD. A total of 45 patients were diagnosed as familial BD; 23 were female, and 22 were male. In our patients, the incidence of familial BD was determined to be 3.9%. The rates for HLA-B5 positivity, ocular involvement, genital ulcers, and erythema nodosum were determined to be 86.6% (26/30), 26.6%, 82.2%, and 60%, respectively. None of the patients had neurological involvement, but 2 had vascular involvement. Conclusion: This study may contribute to the epidemiological data of BD from Turkey. (C) 2019 S. Karger AG, BaselPublication Retrospective analysis of the forty-six patients with bullous pemphigoid followed-up in our clinic(Deri Zuhrevi Hastaliklar Dernegi, 2016-01-01) Yazıcı, Serkan; BÜLBÜL BAŞKAN, EMEL; YAZİCİ, SERKAN; Başkan, Emel Bülbül; Tunalı, Şükran; Aydoğan, Kenan; AYDOĞAN, KENAN; Sarıcaoğlu, Hayriye; SARICAOĞLU, HAYRİYE; Tıp Fakültesi; Deri ve Zührevi Hastalıkları Ana Bilim Dalı; 0000-0001-6407-0962; 0000-0002-0193-1128; AAH-1388-2021; AAH-6216-2021; AAH-2459-2021Background and Design: Bullous pemphigoid (BP) is an autoimmune disease characterised by widespread itchy plaques and subepithelial blisterings and usually affects the elderly population. Due to the chronic nature of the disease, to prevent the side effects of chronic steroid treatment, adjuvant immunosuppressive (mycophenolate mofetil, azathioprine, methotrexate) and anti-inflammatory (tetracycline, nicotinamide, dapsone) agents may be used. In this study, we retrospectively evaluated the clinical and demographic characteristics and applied treatments of 46 patients with the diagnosis of BP and compared with literature data.Materials and Methods: We retrospectively evaluated the records of 46 patients who received clinical and histopathological diagnosis of BP and followed up in our clinic between 2006 and 2013.Results: Of the 46 patients, 22 were female and 24 male. The mean age of onset was 69.54 years (range: 18-105). The duration of the lesion ranged from 1 week to 10 months with a median duration of 8 weeks. The most frequent comorbid chronic disease was hypertension detected in 28 (60.8%) patients. Only four patients had a history of malignancy before the onset of the disease. Nineteen patients (42%) used more than 5 agents for comorbid diseases. Thirty-two patients (69.5%) used systemic corticosteroids alone and ten (22%) patients needed additional adjuvant therapies.Conclusion: BP is a major cause of morbidity in the elderly population receiving multiple drug treatment. To avoid the side effects of steroid therapy, especially in patients with severe disease, short-term use of additional immunosuppressive agents appears to be safe and effective.Publication Is there any association between mycosis fungoides and Th-1,Th-2 cytokines and transforming growth factor-beta 1 gene polymorphisms?(Deri Zuhrevi Hastaliklar Dernegi, 2018-01-01) Yazıcı, Serkan; YAZİCİ, SERKAN; Aydoğan, Kenan; AYDOĞAN, KENAN; Sarıcaoğlu, Hayriye; SARICAOĞLU, HAYRİYE; BÜLBÜL BAŞKAN, EMEL; Tunalı, Şükran; Tıp Fakültesi; Dermatoloji Ana Bilim Dalı; 0000-0001-6407-0962; 0000-0002-0193-1128; AAH-2459-2021; AAH-1388-2021; AAH-6216-2021Background and Design: Cytokines are considered to play a crucial role in the development of mycosis fungoides (MF). Cytokine production is under genetic control and allelic variations of cytokine genes are associated with lower or higher production of cytokines. The aim of this study was to determine any possible cytokine gene polymorphisms that may be a risk factor for the development or progression of MF.Materials and Methods: Genotyping of interferon-gamma (IFN-gamma)+874, interleukin (IL)-10-1082, IL-6-174, transforming growth factor-beta 1 (TGF-beta 1), codon 10 and codon 25, and tumor necrosis factor-alpha (TNF-alpha)-308 was undertaken in 55 Turkish patients with MF and compared to 50 healthy controls. Polymerase chain reaction (PCR)-restriction fragment length polymorphism was applied for IFN-gamma+874, IL-10-1082, IL6-174 and TNF-alpha-308 gene polymorphisms. TGF-beta 1 was genotyped by direct DNA sequencing of PCR amplified gene products for codon 10 and codon 25 polymorphisms.Results: Genotype distributions showed no significant difference between the patients and the controls for any of the five investigated cytokines. There was no significant difference between advanced stage and early stage cases and healthy controls.Conclusion: None of the studied cytokine gene polymorphisms are risk factors for the development or progression of MF in the Turkish population, however, further studies are needed.Publication Factors related to omalizumab drug survival and treatment responses in chronic urticaria(Karger, 2022-08-29) Hasal, Eda; SARICAOĞLU, HAYRİYE; Bülbül Başkan, Emel; BÜLBÜL BAŞKAN, EMEL; YAZİCİ, SERKAN; Yazıcı, Serkan; Aydoğan, Kenan; AYDOĞAN, KENAN; Tıp Fakültesi; Dermatoloji Ana Bilim Dalı; 0000-0001-6310-5107; 0000-0001-6407-0962; 0000-0002-0193-1128; AAH-6216-2021Introduction: This study aimed to evaluate factors affecting drug survival and treatment response in patients with chronic urticaria treated with omalizumab in clinical practice. Methods: This study included 386 patients with chronic urticaria. Demographic characteristics, clinical features, laboratory parameters, and omalizumab treatment data were analyzed retrospectively. The 7-day urticaria activity score (UAS7) and urticaria control test (UCT) were used to assess disease severity and treatment responses. Results: Well-controlled disease (UAS7 <= 6) was achieved in 59.3% of patients at a median of 2 months. Complete response was significantly higher in patients treated with omalizumab for >= 12 months (p < 0.001). Family history of asthma (p = 0.01) was less frequent, and disease duration (p = 0.041) was shorter in patients with well-controlled disease. Total treatment duration was longer in patients with relapse (p < 0.001) and serum Helicobacter pylori IgA positivity (p = 0.029). Discussion/Conclusion: Treatment response is better in patients treated with omalizumab for >= 12 months. However, prolonged treatment does not prevent relapse. Our findings suggest that continuous or intermittent therapy is an appropriate alternative treatment option in patients with severe chronic urticaria; however, continuous therapy can be preferred to maintain the patient's quality of life.Publication Erythema nodosum epidemiology: 5-year retrospective study(Wolters Kluwer Medknow Publications, 2012-09-01) Öz, Arife; Aydoğan, Kenan; Adım, Saduman Balaban; İzol, Belçin; Sarıcaoğlu, Hayriye; Başkan, Emel Bülbül; Tunalı, Şükran; Öz, Arife; AYDOĞAN, KENAN; BALABAN ADIM, ŞADUMAN; SARICAOĞLU, HAYRİYE; BÜLBÜL BAŞKAN, EMEL; Tunalı, Sükran; Tıp Fakültesi; Deri ve Zührevi Hastalıklar Ana Bilim Dalı; 0000-0002-0144-3263 ; JQC-1664-2023; AAH-6216-2021; EMN-0789-2022; DPU-8534-2022; AAH-1388-2021; GGH-7385-2022Objective: Erythema nodosum (EN) is the most common type of septal panniculitis. Although triggering factors of EN are drugs, infections, malignancies, inflammatory diseases however disease is idiopathic in 32-72%. Factors are changing from region to region and from country to country. In this study, our aim was to investigate the etiologic factors and to evaluate the clinic and laboratory findings of EN.Methods: Sixty-six patients who were histopathologically diagnosed as EN in our department between 2005 and 2010 were included to this study. Demographic data and treatment were evaluated.Results: Fifty-two of 66 patients had underlying etiologic factors (Group 1) and 14 of were idiopatic (Group 2). Most common etiologic factor was Behcet's disease (n=15), and followed by drug (n=13), sarcoidosis (n=10), upper respiratory tract infection (n=6), autoimmune disease (n=4), pregnancy (n=2), tuberculosis (n=2) in decreasing frequencies. In our study malignancy and inflammatory bowel disease are not appointed.Conclusion: Behcet's disease is a rare cause of EN. In other studies in our country the idiopatic group was in majority. In our study because of finding the common etiologic factor as Behcet's disease due to being of Behcet's disease high prevalance (11-42/10000) in our country and existence of Behcet's disease center in our facultyPublication Prevalence of hirsutism in Turkey: Data of the dermatoendocrinology study group(Wiley, 2023-12-26) Cebeci Kahraman, Filiz; Temiz, Selami Aykut; Erdoğan, Sevil Savas; Öztürk, Perihan; Güven, Munevver; Çelik, Hilal Ayvaz; Tellal, Ebru Sarıkaya; Akbayrak, Atiye; Selçuk, Leyla Baykal; Akbulak, Özge; Emre, Selma; Gencoğlan, Gülsüm; Ataseven, Arzu; Kaya Erdogan, Hilal; Ertekin, Sümeyre Seda; Tasolar, Mustafa Kaan; An, Isa; Öztürk, Murat; Karakuzu, Ali; Erdal, Semahat Alp; Solak, Sezgi Sarıkaya; Albayrak, Hülya; Cömert Özer, Elif; Bayramgürler, Dilek; Özgöztaşı, Orhan; Yülek, Tuğba; Zindanci, Ilkin; Çalıkoğlu, Emel; Kuş, Celal; Aydogan, Kenan; AYDOĞAN, KENAN; Tıp Fakültesi; Dermatoloji Ana Bilim DalıPublication Acrodermatitis dysmetabolica with argininosuccinate lyase deficiency(Scientific Scholar Llc, 2023-11-01) Öztürk, Ferdi; ÖZTÜRK, FERDİ; SARICAOĞLU, HAYRİYE; Ünlü, Cansu Irmak; ÜNLÜ, CANSU IRMAK; Sarıcaoğlu, Hayriye; Aydoğan, Kenan; AYDOĞAN, KENAN; Erdöl, Şahin; ERDÖL, ŞAHİN; Tıp Fakültesi; Dermatoloji Ana Bilim Dalı; G-2588-2013Publication Flow cytometric analysis of T, B, and NK cells antigens in patients with mycosis fungoides(Hindawi, 2015-11-24) Yazıcı, Serkan; Başkan, Emel Bülbül; Budak, Ferah; Oral, Barbaros; Adım, Şaduman Balaban; Kalın, Zübeyde Ceylan; Özkaya, Güven; Aydoğan, Kenan; Sarıcaoğlu, Hayriye; Tunalı, Şükran; YAZİCİ, SERKAN; BÜLBÜL BAŞKAN, EMEL; BUDAK, FERAH; ORAL, HALUK BARBAROS; BALABAN ADIM, ŞADUMAN; Kalın, Zübeyde Ceylan; ÖZKAYA, GÜVEN; AYDOĞAN, KENAN; SARICAOĞLU, HAYRİYE; Tunalı, Şükran; Tıp Fakültesi; Dermatoloji ve Zührevi Hastalıklar Ana Bilim Dalı; 0000-0001-6407-0962; 0000-0001-7625-9148; 0000-0003-0463-6818; 0000-0003-0297-846X; 0000-0002-0193-1128; IZP-9398-2023; AAH-2459-2021; AAH-1388-2021; A-4421-2016; F-4657-2014; AAH-6216-2021; K-7285-2012; EMN-0789-2022; CWV-8710-2022; DPU-8534-2022; GGH-7385-2022We retrospectively analyzed the clinicopathological correlation and prognostic value of cell surface antigens expressed by peripheral blood mononuclear cells in patients with mycosis fungoides (MF). 121 consecutive MF patients were included in this study. All patients had peripheral blood flow cytometry as part of their first visit. TNMB and histopathological staging of the cases were retrospectively performed in accordance with International Society forCutaneous Lymphomas/European Organization of Research and Treatment of Cancer (ISCL/EORTC) criteria at the time of flow cytometry sampling. To determine prognostic value of cell surface antigens, cases were divided into two groups as stable and progressive disease. 17 flow cytometric analyses of 17 parapsoriasis (PP) and 11 analyses of 11 benign erythrodermic patients were included as control groups. Fluorescent labeled monoclonal antibodies were used to detect cell surface antigens: T cells (CD3(+), CD4(+), CD8(+), TCR alpha beta(+), TCR gamma delta(+), CD7(+), CD4(+) CD7(+), CD4(+) CD7(-), and CD71(+)), B cells (HLA-DR+, CD19(+), and HLA-DR(+)CD19(+)), NKT cells (CD3(+)CD16(+)CD56(+)), and NK cells (CD3(-)CD16(+)CD56(+)). The mean value of all cell surface antigens was not statistically significant between parapsoriasis and MF groups. Along with an increase in cases of MF stage statistically significant difference was found between the mean values of cell surface antigens. Flow cytometric analysis of peripheral blood cell surface antigens in patients with mycosis fungoides may contribute to predicting disease stage and progression.